Technology
Health
Biotechnology

Five Prime Therapeutics

$9.05
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.24 (2.72%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell FPRX and other stocks, options, ETFs, and crypto commission-free!

About

Five Prime Therapeutics, Inc. Common Stock, also called Five Prime Therapeutics, is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. Read More The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.

Employees
209
Headquarters
South San Francisco, California
Founded
2001
Market Cap
315.29M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
332.91K
High Today
$9.12
Low Today
$8.86
Open Price
$8.86
Volume
102.91K
52 Week High
$18.57
52 Week Low
$7.84

Collections

Technology
Health
Biotechnology
Therapy
Medical
Cancer Prevention
2013 IPO
US

News

Yahoo FinanceMay 8

Five Prime Therapeutics (FPRX) Reports Q1 Loss, Misses Revenue Estimates

Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 4.67% and -6.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

28
Yahoo FinanceMay 8

Five Prime Therapeutics Reports First Quarter 2019 Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced its results for the first quarter and provided an update on the company’s recent activities. The company also provided an update on the Phase 3 FIGHT trial testing bemarituzumab in combination with mFOLFOX6 in patients with gastric (GC) or gastroesophageal junction (GEJ) cancer that...

2
Yahoo FinanceMay 7

See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

Five Prime Therapeutics Inc NASDAQ/NGS:FPRX View full report here! Summary ETFs holding this stock are seeing positive inflows Bearish sentiment is moderate Economic output in this company's sector is expanding Bearish sentiment Short interest | Neutral Short interest is moderate for FPRX with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors...

4

Earnings

-$1.54
-$1.21
-$0.88
-$0.55
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.